New drugs for heart failure plus review chart

The pharmacotherapy management of patients with heart failure with reduced ejection fraction is a populated landscape with multiple drugs affecting morbidity and mortality.  Two new medications that are the first in two new classes were approved recently - a neprilysin inhibitor and a hyperpolarization-activated cyclic nucleotide-gated channel blocker.

But first here's a quick table and a few notes about the current use of medications for treating heart failure with reduced ejection fraction.